Working with mice, hamsters, and nonhuman primates, Penn researchers found that a modified version of the mRNA COVID-19 ...

Moderna – at the moment embroiled in a patent dispute with Pfizer and BioNTech over mRNA intellectual property – is also testing a vaccine that combines COVID-19 and flu in a single jab in a ...

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

Novavax is approved for children aged 12 and older. Both Moderna and Pfizer-BioNTech vaccines use messenger RNA (mRNA), which ...

On Aug. 22, the Food and Drug Administration approved and authorized newer formulations of the two mRNA vaccines, from Pfizer ...

1-lineage omicron variants of the coronavirus, or SARS-CoV-2. The options include the mRNA vaccines from Pfizer/BioNTech and ...

With this in mind, is the luster of mRNA companies like BioNTech and Moderna gone? Are they one-trick ponies who found tremendous success only with COVID vaccines? Is either one worth investing in?

BioNTech, founded in 2008 in Germany, has become a key player in the development of personalized mRNA cancer treatments. The emerging biotech's first commercial vaccine, for covid, received its ...

Welcome to BioNTech's third quarter 2024 earnings call. I would like to hand the call over to Michael Horowicz Director, Investor Relations. Please go ahead.

Presented clinical data for multiple assets across modalities, including bispecific antibody candidate BNT327/PM8002 and mRNA cancer vaccine ...

Working with animals, Penn researchers modified the mRNA vaccine to target C. difficile, an infection that kills 30,000 in ...

On Aug. 22, the Food and Drug Administration approved and authorized newer formulations of the two mRNA vaccines, from Pfizer/BioNTech and Moderna, for ages 6 months and up. About a week later ...